BIOPTIMUS
20.2.2024 09:01:26 CET | Business Wire | Press release
Today, French startup Bioptimus emerged from stealth following a seed funding round of $35M. Under the leadership of Professor Jean-Philippe Vert, PhD, Bioptimus unites a world-class team of scientists from Owkin and Google DeepMind alumni to transform biology with cutting-edge AI foundation model technologies that capture the various scales of biology. This funding round is led by Sofinnova Partners, with Bpifrance Large Venture, and additional support from global funds based in France, including Frst and multistage VC Cathay Innovation. Top global tech investors Headline, Hummingbird, NJF Capital, Owkin and Top Harvest Capital, as well as notable tech entrepreneur Xavier Niel, have joined the round to create a global leader in AI for biology in France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220205004/en/
Professor Jean-Philippe Vert, PhD, co-founder and CEO of Bioptimus, Chief R&D Officer of Owkin and former Research Lead at Google Brain, said: “The application of foundation models and generative AI to biology is set to have a profound impact in science. By harnessing the power of foundation models and advanced algorithms trained on massive amounts of biological and multimodal data across scales, we aim to capture the laws of biology that have hitherto remained too complex to be properly understood. This holistic understanding of biology across scales will be critical to accelerate biomedical and environmental science.”
Edward Kliphuis, Partner at Sofinnova Partners, added: “Foundation models in biology are game-changers. They unlock unprecedented potential to personalize medicine, capturing the uniqueness of each individual while harnessing the collective knowledge of all. Bioptimus stands out by seamlessly blending unparalleled data resources and access, elite talent, and extensive computational power. Together with Sofinnova's deep expertise in life sciences and our expansive network, we're poised to redefine the future of the industry."
Laurent Higueret, Senior Investment Director at Bpifrance Large Venture, commented: “Founded on the ambition to make a quantum leap in our understanding of the complexity of human biology and bringing together a top team of accomplished experts in the fields of data science and generative AI, Bioptimus holds the promise to go even deeper in the analysis of patients’ data across multiple levels and help unveil biological connections hitherto unthought-of. We at Bpifrance are delighted to team-up with such an impressive team and group of investors and support the development of a category defining company that has the potential to disrupt many R&D activities.”
Bioptimus will benefit from Owkin’s data generation capabilities and federated global access to multimodal patient data sourced from leading academic hospitals worldwide, as well as a best-in-class, scalable and secure computing environment from Amazon Web Services, Inc (AWS). Fueled by an abundance of data from all scales and modalities, this gives the power to create computational representations that establish a strong differentiation against models trained solely on public datasets and a single data modality that are not able to capture the full diversity of biology.
About Bioptimus
Bioptimus is building the first universal AI foundation model in biology to drive advancements in scientific research and biotechnological innovation. Leveraging a team of world-class experts, employing state-of-the-art AI technologies and accessing unique proprietary data at scale, we aim to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond. For more information, please visit https://www.bioptimus.com.
About Owkin
Owkin is a TechBio company that combines the best of human and artificial intelligence to ensure every patient gets the right treatment. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials and develop AI diagnostics. Owkin uses privacy-enhancing federation to access up-to-date multimodal patient data that unlocks AI’s potential to power precision medicine. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation. Owkin founded MOSAIC, the world’s largest multi-omics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and Bpifrance, among others).
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners invests in companies from seed to late-stage, and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop innovations that will positively impact our collective future.
Founded in 1972, Sofinnova Partners has backed over 500 companies and created market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com
About Bpifrance and its Large Venture fund
Bpifrance is the French Public Investment Bank and acts as one-stop-shop offering domestic companies a comprehensive range of financial products and services to support them at every stage of their development including equity, loans, guarantees and export insurances, as well as consultancy or training.
Large Venture - the late-stage VC arm of Bpifrance - is a €1.75 billion fund dedicated to fast-growing, highly innovative startups looking to accelerate organic or external growth. Large Venture was incepted in 2013 with the mission to bring the most promising French technologies from the lab to the market, and ultimately to profitability. Large Venture invests in private and public companies across three main sectors: healthtech and life sciences, digital and greentech. For more information, please visit us at: bpifrance.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220205004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel SP900BF-AP Smart Module Sets the Pace for Edge AI with 100 TOPS of Computing Power11.11.2026 10:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced the SP900BF-AP, a smart module that lets robots, inspection systems and edge gateways run large AI models on the device itself. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111252890/en/ Quectel SP900BF-AP smart module sets the pace for Edge AI with 100 TOPS of computing power Built on the Qualcomm Dragonwing™ IQ-9075 Processor and delivering up to 100 TOPS of on-device AI compute, the module enables industrial OEMs to integrate advanced AI directly into their products, reducing latency, bandwidth costs and data privacy risks associated with cloud-based processing. By processing data locally, manufacturers can support real-time robotics, automated inspection and other demanding industrial applications while retaining greater control over sensitive production data. Long-term hardware availability also helps meet the extended product l
Quectel Expands 5G Antenna Portfolio With Ten Versatile Combo Solutions, From Compact 2-In-1 to Rugged 9-In-1 Designs11.11.2026 10:00:00 CET | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces ten external combo antennas that combine 5G with GNSS, Wi-Fi or both in a single housing. Instead of specifying, fitting and testing a separate antenna for each radio, device makers can choose one unit matched to the size, technology mix and operating environment of their deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111461614/en/ Quectel expands 5G antenna portfolio with ten versatile combo solutions, from compact 2-in-1 to rugged 9-in-1 designs Across the family, each antenna combines multiple omnidirectional elements with high isolation between them to limit self-interference. Most models cover 5G from 600MHz to 6000MHz and remain backward compatible with 4G, 3G, 2G, LTE Cat-M and NB-IoT networks. All support screw mounting, some also adhesive mounting, and housings are built for outdoor use with ratings from IP65 up to IP69K. “Ev
Lattice and NXP Deliver Flexible, Secure Computing Solution for the Industrial Edge10.11.2026 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced the Lattice NXP PCIe® Companion solution, jointly enabled and promoted with NXP® Semiconductors. Pairing NXP’s i.MX 95 applications processor with Lattice Nexus™-based FPGAs over PCIe, the solution addresses the real-time connectivity, deterministic I/O, and security challenges in industrial automation, robotics, and intelligent edge applications. The joint solution is available in Lattice CertusPro™-NX or Lattice Certus™-NX configurations as companion chips to NXP i.MX 95 SoC compute processors, deepening a long-standing collaboration between Lattice and NXP spanning industrial, data center, and networking applications. The Lattice FPGA adds low latency, deterministic I/O alongside the NXP applications processor, delivering combined capabilities across real-time processing, AI, and custom I/O to help customers modernize aging designs for new interface standards. It supports e
FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor10.11.2026 19:14:00 CET | Press release
PIMJETMI is a new once-daily oral systemic treatment option for certain U.S. patients with symptomatic tenosynovial giant cell tumor (TGCT)In the Phase 3 MANEUVER trial, PIMJETMI demonstrated early1 and durable2 tumor response with clinically meaningful improvements in all clinical outcome assessments, including physical function and painPIMJETMI has shown high objective response rate (ORR) with a manageable safety profileNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. “People living with TGCT have long faced difficult treatment decisions as they navigate a disease that can significant
Smartsheet Integrates With Claude Sheets, Making It Easy to Start Projects in Claude and Launch Workflows Across Teams with Smartsheet10.11.2026 18:57:00 CET | Press release
New Send to Smartsheet feature moves work started in Claude into Smartsheet, where the Execution Graph connects it to the people, plans and goals that see it through Smartsheet, the AI-powered enterprise work management platform, today announced a new integration with Claude Sheets, the new spreadsheet artifact in Claude from Anthropic, now in beta. With the new Send to Smartsheet feature, people who build a tracker or plan in Claude can move it into Smartsheet in a few clicks. There they can put it to work with their team, connected to the plans, projects, people and systems their organization already runs on. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110763156/en/ With the new Send to Smartsheet feature, people who build a tracker or plan in Claude can move it into Smartsheet in a few clicks. More and more work now begins in a conversation with Claude, and the Smartsheet MCP connector for Claude puts the entire pow
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom